Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ricin is a highly potent toxin and lectin produced in the seeds of the castor oil plant, *Ricinus communis*. It is a glycosylated heterodimeric protein consisting of an A chain (RTA), which inhibits ribosomes, and a B chain (RTB), which facilitates cellular entry. Exposure can lead to severe symptoms including pulmonary edema, gastrointestinal distress, and multi-organ failure. There is no antidote, and treatment is supportive.
Ricin A chain (RTA) functions as an N-glycoside hydrolase that irreversibly inactivates ribosomes by removing an adenine residue from rRNA, halting protein synthesis. Ricin B chain (RTB) binds terminal galactose residues on cell surfaces, facilitating entry of the A chain into cells via endocytosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ricin (None).